Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms AERN
- 07 Nov 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Sep 2019 to 1 Nov 2019.
- 06 Nov 2019 Trial design presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 24 Jul 2019 Planned primary completion date changed from 1 Mar 2020 to 1 May 2021.